Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 2,652 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical Clear all
Terminated Phase 1Phase 2 Interventional Results available

Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis

NCT03847389
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Clobetasol propionate 0.05% Topical Oil
Drug
Lead sponsor
Hill Dermaceuticals, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Sanford, Florida • Savannah, Georgia • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Vibrating, Cold Device for Pediatric Intravenous (IV) Cannulation Pain Relief

NCT01394250
View directory record Official record
Conditions
Pain, Anxiety
Interventions
Buzzy, Topical Lidocaine 4% Cream
Device · Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years to 18 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2016 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Phase 3 Interventional

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

NCT03331523
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Calcipotriene/Betamethasone Dipropionate, Taclonex®, Placebo
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
31
States / cities
Encinitas, California • Fremont, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Phase 4 Interventional

A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis

NCT00106496
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Protopic, Corticosteroid, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
2 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
24
States / cities
Birmingham, Alabama • Irvine, California • Loma Linda, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2

NCT03017846
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
Cantharidin
Drug
Lead sponsor
Steven R Cohen
Other
Eligibility
2 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Topical Cyclosporine and Disease Progression

NCT00567983
View directory record Official record
Conditions
Disease Progression, Disease Severity, Staining, Schirmers, OSDI
Interventions
Restasis, Endura
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women

NCT02364882
View directory record Official record
Conditions
Female Sexual Health
Interventions
Sildenafil
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Phase 1 Interventional

A Study of the Systemic Absorption of MOB015B

NCT03244280
View directory record Official record
Conditions
Onychomycosis
Interventions
MOB015B
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
12 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 29, 2026, 6:21 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis

NCT04033562
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Use, Opioid Dependence, Opioid Abuse, Medication Assisted Treatment, Infusion Catheter, Wound, Lidopatch, Ambu ACTion, Pregnancy Related, Cesarean Section
Interventions
Lidocaine patch, Ambu ACTion pump, 0.125% bupivacaine at 8cc/hr
Drug · Device
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study

NCT04355286
View directory record Official record
Conditions
Absorption; Chemicals, Sunscreening Agents
Interventions
Bemotrizinol
Drug
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Tetracaine 0.5% and Lidocaine 2% Jelly for Topical Phacoemulsification Cataract Surgery

NCT00827073
View directory record Official record
Conditions
Cataracts
Interventions
tetracaine 0.5%, Lidocaine 2% Jelly
Drug
Lead sponsor
Hermann Eye Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Oct 29, 2026, 6:21 PM EDT
Not listed Phase 1Phase 2 Interventional

Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome

NCT06570941
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Chylobinoid Topical Cream
Drug
Lead sponsor
Synthonics Inc
Industry
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 29, 2026, 6:21 PM EDT
Terminated Phase 4 Interventional Results available

Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse

NCT01886794
View directory record Official record
Conditions
Pelvic Floor Disorders
Interventions
Postmenopausal, topical vaginal estrogen cream, Placebo Comparator: Postmenopausal, topical placebo cream
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
21 Years to 70 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects

NCT01068158
View directory record Official record
Conditions
Head Lice
Interventions
0.5% Ivermectin Cream, Placebo control
Drug
Lead sponsor
Topaz Pharmaceuticals Inc
Industry
Eligibility
5 Months and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
7
States / cities
Little Rock, Arkansas • Delray Beach, Florida • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 29, 2026, 6:21 PM EDT
Active, not recruiting Phase 2 Interventional

Clinical Application of Stem Cell Educator Therapy in Alopecia Areata

NCT04011748
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions
Stem Cell Educator therapy
Combination Product
Lead sponsor
Throne Biotechnologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Phase 3 Interventional Results available

The Safety and Efficacy of SYD-101 in Children With Myopia

NCT03918915
View directory record Official record
Conditions
Nearsightedness, Near Sightedness, Near-sightedness
Interventions
SYD-101 0.01%, SYD-101 0.03%, Vehicle
Drug
Lead sponsor
Sydnexis, Inc.
Industry
Eligibility
3 Years to 14 Years
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
41
States / cities
Irwindale, California • Pasadena, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 29, 2026, 6:21 PM EDT
Not listed Not applicable Interventional

Dapsone Prurigo Study

NCT01870050
View directory record Official record
Conditions
Lichen Simples Chronicus and Prurigo
Interventions
Dapsone gel - verum
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 29, 2026, 6:21 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma

NCT06561321
View directory record Official record
Conditions
Palmoplantar Keratoderma
Interventions
Tapinarof
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris

NCT03717506
View directory record Official record
Conditions
Acne Vulgaris
Interventions
GDC 268 Lotion, Clindamycin Phosphate Lotion 1%, GDC Vehicle Lotion
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
34
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Not applicable Interventional

A Prospective Study of the Effect of Topical Sodium Hyaluronate Immediately Post-PKP on Time to Reepithelialization

NCT00570648
View directory record Official record
Conditions
Corneal Transplantation
Interventions
sodium hyaluronate
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Phase 2 Interventional Results available

CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

NCT02617667
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine A, Placebo
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years to 99 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Not applicable Interventional

Post Market Usability Evaluation Of The PicoSure Pro Device

NCT05102617
View directory record Official record
Conditions
Wrinkle, Acne Scars, Benign Epidermal Pigmented Lesions, Benign Dermal Pigmented Lesions, Tattoo Removal
Interventions
PicoSure Pro Device, PicoSure Device, Topical Cosmeceuticals
Device · Drug
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Sacramento, California • Westford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Phase 4 Interventional

Response of Children With Atopic Dermatitis (Eczema) to Eucrisa

NCT04023084
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Crisaborole
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
4 Months to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 29, 2026, 6:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.

NCT06130384
View directory record Official record
Conditions
Pain, Intravitreal Injection, Pain, Acute
Interventions
Use of bromfenac 0.09% to reduce intravitreal injection pain, Use of artificial tears to reduce intravitreal injection pain
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 99 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Boston, Massachusetts • Bethlehem, Pennsylvania • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 29, 2026, 6:21 PM EDT